Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
NCT01521689
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
Rituximab
Sponsor
Institut Paoli-Calmettes